DABE, dabigatran etexilate; DAB, dabigatran; CES1, human carboxylesterase 1; CES2, human carboxylesterase 2; HLS9, human liver S9; HIM, human intestinal microsomes; BNPP, bis(4-nitrophenyl) phosphate; LC-MS/MS, liquid chromatography/triple quadrupole mass spectrometer; DAB-d3, dabigatran-d3; COC, cocaine; BE, benzoylecgonine; EME, ecgonine methyl ester; CE, cocaethylene; K m , Michaelis constant; V max , maximum velocity; CL int , in vitro intrinsic clearance. pmol/min/mg protein). Sequential hydrolysis of DABE in human intestinal microsomes followed by hydrolysis in human liver S9 fractions resulted in complete conversion to DAB. These results suggest that after oral administration of DABE to humans, DABE is hydrolyzed by intestinal CES2 to the intermediate M2 metabolite followed by hydrolysis of M2 to DAB in the liver by CES1. Carboxylesterase-mediated hydrolysis of DABE was not inhibited by alcohol.
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Abstract:
Dabigatran etexilate (DABE) is an oral prodrug that is rapidly converted to the active thrombin inhibitor, dabigatran (DAB), by serine esterases. The aims of the present study were to investigate the in vitro kinetics and pathway of DABE hydrolysis by human carboxylesterase enzymes, and the effect of alcohol on these transformations. The kinetics of DABE hydrolysis in two human recombinant carboxylesterase enzymes (CES1 and CES2), and in human intestinal microsomes and human liver S9 fractions were determined. The effects of alcohol (a known CES1 inhibitor) on the formation of DABE metabolites in carboxylesterase enzymes and human liver S9 fractions were also 
Introduction
The direct thrombin inhibitor dabigatran etexilate (DABE) is a new oral anticoagulant approved in the United States to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation (Connolly et al., 2009) . Dabigatran (DAB), the active moiety, is not orally bioavailable, so it is administered as a double prodrug (DABE) to improve absorption. The DABE prodrug is quickly converted to the active compound as DAB plasma concentrations peak rapidly after an oral dose and the two primary intermediate metabolites, as well as the DABE plasma concentrations are very low (Stangier et al., 2007; Stangier et al., 2008) . This finding indicates that DABE undergoes a high first-pass metabolism prior to reaching the systemic circulation.
The conversion of DABE to DAB is a two-step process involving hydrolysis of an ethyl ester and a carbamate ester producing the active moiety (Blech et al., 2008) .
Experiments conducted in vitro using human liver microsomes confirm that enzymatic hydrolysis by serine hydrolases is the primary pathway for the formation of DAB from DABE and that the cytochrome P450 system plays no significant role in forming the active metabolite (Blech et al., 2008) . Although the specific esterases involved in DABE metabolism have not been identified, the structure of DABE would suggest that human carboxylesterase-1 (CES1) and human carboxylesterase-2 (CES2) are likely to play a role in the formation of the DAB active metabolite (Satoh et al. 2002; Imai et al. 2006b ).
Furthermore based on the known substrate specificity of these enzymes, it would be predicted that CES1 hydrolyzes the DABE ethyl ester whereas CES2 would metabolize the carbamate ester (Imai, 2006a; Hu et al., 2013) .
However, the specific hydrolytic pathways and the relative contributions of CES1 and CES2 to the formation of the DAB active metabolite have not been studied.
Identification of the specific in vivo metabolic pathway is essential for understanding potential factors affecting the safety and efficacy of DABE given the concentrationdependent anticoagulant effect of the DAB active metabolite and the correlation between DAB plasma concentrations and risk of stroke and bleeding (Stangier et al., 2007; Stangier, 2008; Harper et al., 2012 . A growing body of evidence suggests that a number of factors can affect the catalytic activity of CES1 and CES2 and result in changes in drug disposition . One such factor is drug interactions that inhibit carboxylesterase function (Parker and Laizure, 2010; Zhu et al., 2010; Rhoades et al., 2012) . It is well established that alcohol is an inhibitor of carboxylesterase-mediated cocaine hydrolysis (Farre et al., 1997; Cami et al., 1998; Song et al., 1999; Laizure et al., 2003; Parker and Laizure, 2010) . Whether this effect of alcohol is specific for cocaine or is more broadly applicable to other CES1 substrates is uncertain. However, recent work showing that alcohol inhibits the hydrolysis of the CES1 substrate drug methylphenidate in humans suggests that the hydrolysis of other CES1 substrate drugs might also be inhibited (Patrick et al., 2007; Bell et al., 2011) .
Given the large number of people who consume alcohol and its known effects on CES1 hydrolysis, understanding the impact of alcohol on carboxylesterase-mediated DABE hydrolysis could have important implications for the safety and efficacy of this agent.
Therefore, the objectives of this study are to characterize the human carboxylesterase-mediated DABE metabolic pathway and to determine the effect of alcohol on carboxylesterase-mediated hydrolysis of DABE. liver S9 fraction (HLS9), and pooled (n = 7 donors of mixed gender) human intestinal microsomes (HIM) were obtained from BD Gentest (San Jose, CA, USA). Human liver cytosol has significant CES1 and CES2 activity therefore HLS9, which contains both cytosolic and microsomal enzymes, was used for in vitro metabolism studies instead of microsomes (Takahashi et al., 2009 ).
In vitro metabolic stability. The metabolic stability of DABE in incubations containing recombinant human CES1, CES2, CES1/CES2 mixture, and HLS9 were performed. 
The stability of DABE (1000 nM) in human plasma was tested with and without BNPP (400 µM), a known specific carboxylesterase inhibitor. The experimental procedure was similar to that of the stability studies with human carboxylesterases except the final acetonitrile concentration was 1% for all assays. The reaction was terminated by the addition of a three-fold volume of ice-cold acetonitrile.
In vitro enzyme kinetics. To determine enzyme kinetics (K m , V max , and CL int ), DABE was incubated with recombinant CES1, CES2, HLS9, and HIM under linear metabolite formation conditions. The experimental procedure was similar to that of the metabolic stability studies except the final substrate concentrations were 0.1, 0.2, 0.5, 1, 5, 10, 50, and 100 μ M in the incubation system. The final acetonitrile concentration was 1% for all assays. The optimal incubation time was 5 minutes. The final protein concentration was 0.25 mg/mL for recombinant CES1, CES2, HLS9 and HIM. All reactions were run in triplicate.
In vitro inhibition. Procedures to determine the effect of alcohol on the carboxylesterase-mediated hydrolysis of DABE were similar to the enzyme kinetics study. However, DABE was first mixed with alcohol at increasing concentrations (0, 12.5, 25, 50, and 100 mM) in the incubation tubes and then recombinant enzyme or HLS9 was added. The alcohol concentration was selected based on the reported human exposure levels (Umulis et al., 2005) . Inhibition was tested under two conditions to other drugs (Hu et al., 2011) . In brief, B 5% from 0.00 to 0.50 minutes; B 100% from 0.51 to 2.00 minutes; B 5% from 2.01 to 4.50 minutes.
The precursor-product ion pairs (singly protonated species) used for multiple reaction monitoring (MRM) of DABE, DAB, DAB-d3, COC, BE, EME, and CE were m/z curves of the analyte/IS peak area ratio of a given analyte vs. the nominal concentration in nM were linear with correlation coefficients >0.99. The lower limit of quantification (LLOQ) was 1.37 nM for all the analytes except for EME (12.3 nM). The within-run and between-run assay accuracies ranged from 93% to 109% and from 95% to 108%, respectively, whereas the ranges of precision values for the assays were 1.8%-12.5% and 1.5%-14.4%, respectively. The two intermediate metabolites (M1 and M2) in the study samples were quantified by our recently developed assay . 
Results
In vitro metabolic stability. To identify the specific enzymes responsible for DABE hydrolysis, separate incubations using recombinant CES1 and CES2 were conducted.
Incubations using a mixture of recombinant CES1 and CES2 were also performed to assess the combined effect of these enzymes. The results of these experiments are summarized in Fig. 1 Furthermore, only a small quantity of the DAB active metabolite is formed in individual CES1 or CES2 incubations (Fig. 1) . In contrast, the formation of DAB in incubations containing both CES1 and CES2 was approximately 4-and 12-fold higher compared to CES1 or CES2 alone, respectively. The metabolic profile of DABE in HLS9 is shown in Fig. 2 . Both M1 (major form) and M2 (minor form) were formed in HLS9. A moderate amount of DAB was also formed (Fig. 2) .
The sequential hydrolysis of DABE in HIM and HLS9 is shown in Fig. 3 . The metabolic depletion of DABE in HIM showed that M2 was the major metabolite and only a small quantity of DAB was formed (Fig. 3A, step 1 ). After addition of HLS9, M2 was rapidly and completely hydrolyzed to DAB (Fig. 3B, step 2) .
The stability study of DABE in human plasma showed that less than 25% of DABE was converted to M1 after a 60 minute incubation (the amounts of M2 and DAB formed were very low; data shown in Supplemental Material Fig. S1 ). The addition of the carboxylesterase inhibitor BNPP did not affect this process, suggesting the slow hydrolysis of DABE in human plasma was spontaneous or mediated by other enzymes.
In vitro enzyme kinetics. The enzyme kinetic results are shown in Table 1 Although the V max for the formation of M1 by CES1 was 9.5-fold higher than the formation of M2 by CES2, the K m for the latter conversion was much lower (5.5 µM)
than that of M1 formation (24.9 µM). The K m value for M1 formation in HLS9 was comparable to that in the recombinant CES1 preparation (33.5 µM vs 24.9 µM). Also, the kinetics for the formation of M2 were comparable between HIM and recombinant CES2 (K m 8.6 µM vs 5.5 µM). The CL int for M2 formation in HLS9 was much less than that for the formation of M1 in HLS9 (2.0 µL/min/mg protein vs 35.0 µL/min/mg protein).
In vitro alcohol inhibition. The effects of alcohol and BNPP on the hydrolysis of DABE by recombinant CES1 and CES2 are shown in Fig. 4 . Alcohol showed no significant inhibitory effect on the hydrolysis of DABE in CES1 or CES2. However, carboxylesterase-mediated hydrolysis of DABE was almost completely inhibited by BNPP (Fig. 4) . The effects of alcohol and BNPP on the hydrolysis of DABE in HLS9 are shown in Fig. 5 . The results are similar to those observed with the recombinant carboxylesterase enzymes. DAB can be quantified in both conditions A and B using HLS9.
Alcohol-mediated inhibition of cocaine metabolism was used to validate the in vitro carboxylesterase substrate-alcohol interaction model. Only CES1 converted cocaine to BE (Supplemental Material Fig. S3A ) and the addition of alcohol resulted in the formation of the transesterification product cocaethylene (data not shown). In contrast, 
Discussion
The primary findings of the present study are that CES1 catalyzes the hydrolysis of DABE to M1 and CES2 catalyzes the hydrolysis of DABE to M2. There was little cross-reactivity of carboxylesterase hydrolysis suggesting that both enzymes are required for the formation of the active metabolite, DAB. We also found that alcohol did not inhibit carboxylesterase-mediated DABE hydrolysis by CES1 or CES2.
The formation of DABE hydrolysis products shown in Table 1 and Fig. 1 is consistent with the reported substrate specificities of CES1 and CES2 with CES1
hydrolyzing DABE to the M1 metabolite (ester hydrolysis) and CES2 hydrolyzing DABE to the M2 metabolite (carbamate hydrolysis) (Imai, 2006a) . Carboxylesterases are considered relatively substrate nonspecific, so it is common for a hydrolysis site to be susceptible to both CES1 and CES2 (though usually one predominates). However, as Table 1 shows, recombinant CES1 and CES2 only produce M1 and M2, respectively, and fail to produce the alternate metabolite. It is also apparent from Table 1 that the inability of CES1 and CES2 to hydrolyze the carbamate and ester groups, respectively, also applies to the M2 and M1 metabolites as the individual incubations conducted with recombinant CES1 and CES2 produce only small quantities of the DAB active metabolite.
Both M1and M2 metabolites were formed in HLS9 fractions (Fig. 2) . The metabolite concentration pattern was as expected since CES1 accounts for 80-95% of hydrolase activity in the liver (Imai et. al., 2006b ). Thus, the high M1 concentrations are consistent with the high levels of hepatic CES1 activity. Similarly, since M2 formation is
15 dependent on CES2 hydrolysis, the low M2 concentrations reflect the low level of hepatic CES2 expression. The incubation of DABE in HLS9 fractions also shows a low amount of DAB active metabolite formation. Compared to oral administration of DABE to humans, in vitro incubations in HLS9 cannot account for the significant pre-hepatic formation of M2 from DABE by CES2 in the intestine (Imai and Ohura 2010, Imai et al. 2006b ). This intestinal M2 formation is supported by sequential hydrolysis experiments showing formation of the M2 intermediate metabolite in HIM followed by the subsequent complete conversion to DAB in HLS9 (Fig. 3) .
Collectively, these experiments demonstrate that hydrolysis of the DABE double prodrug by both CES1 (ethyl ester) and CES2 (carbamate ester) is required for formation of the DAB active moiety. When this drug is given to humans, DAB is rapidly formed with peak concentrations occurring within two hours after an oral dose, with negligible plasma concentrations of M1, M2, and DABE (Blech et al. 2008; Stangier et al., 2008) . This indicates that the hydrolysis of both the ethyl and carbamate ester sites undergo high first-pass metabolism prior to reaching the systemic circulation. Based on these findings, a proposed metabolic pathway for DABE after oral administration to humans is shown in Fig. 6 . Our data suggest that DABE undergoes extensive presystemic conversion to M2 by intestinal CES2. The M2 metabolite is then subject to further first-pass hydrolysis by hepatic CES1 resulting in formation of the DAB active metabolite. This proposed metabolic pathway is supported by the sequential hydrolysis of DABE by HIM and HLS9 shown in Figure 3 . Also, this proposed metabolic pathway is consistent with the anatomic locations of CES1 (liver) and CES2 (intestine) expression (Satoh et al. 2002; Imai et al. 2006b ), the specific susceptibility of the ethyl and
16 carbamate esters to hydrolysis by CES1 and CES2 (Table 1) , and the disposition of DABE demonstrated in human studies (Blech et al. 2008; Stangier et al. 2008) . If there were large first-pass formation of the M1 metabolite via CES1-mediated ester hydrolysis, then high plasma concentrations of M1 would be expected, as this metabolite would not be subsequently exposed to the high CES2 activity in the intestines. In this case, DAB formation would depend on the relatively low levels of hepatic CES2. Thus, as shown in Fig. 6 , we propose that the conversion of DABE to M1 to DAB represents a minor metabolic pathway with the primary formation of the DAB active metabolite occurring via CES2-mediated hydrolysis of DABE to M2 that is subsequently hydrolyzed by hepatic CES1 to DAB.
Alcohol has been shown to inhibit cocaine hydrolysis catalyzed by CES1 and CES2 (Roberts et al., 1993; Song et al., 1999) and the hydrolysis of methylphenidate (Bourland et al., 1997) and clopidogrel (Tang et al., 2006 ) (all by CES1) in microsomes or HLS9. In human studies, cocaine and methylphenidate hydrolysis are significantly inhibited by the consumption of alcohol and the transesterification products, cocaethylene and ethylphenidate are produced (Farre et al., 1997; Cami et al., 1998; Patrick et al., 2007) . These studies show that the inhibition of carboxylesterase hydrolysis and the formation of transesterified metabolites are not unique to the cocaine-alcohol interaction and may occur with other CES1 substrates. However, unlike cocaine, dabigatran hydrolysis was not affected by alcohol and no transesterified product was formed (see Fig. 4 and 5). Though BNPP significantly inhibited the hydrolysis of DABE by CES1 and CES2, even alcohol concentrations up to 100 mM did not significantly affect the hydrolysis of DABE by CES1 or CES2. Thus, though past
17 studies clearly demonstrate that the inhibition of CES1 by alcohol occurs with some CES1 substrates, the lack of effect on DABE hydrolysis indicates that the inhibitory effects of alcohol on CES1 cannot be generalized to all CES1 substrates. The potential mechanism(s) for the inability of alcohol to inhibit DABE hydrolysis are unclear.
Although speculative, the lack of formation of transesterified metabolites and the absence of alcohol-mediated inhibition of DABE hydrolysis may be linked. Other CES1 substrate drugs that are inhibited by alcohol also undergo transesterification including cocaine, methylphenidate, clopidogrel, and meperidine (Song et al., 1999; Farre et al., 1997; Patrick et al., 2007; Tang et al., 2006; Bourland et al., 1997) . Also, the molecular weight of DABE is 2-3 fold higher than these other CES1 substrate drugs that are susceptible to inhibition/transesterification with alcohol. This could potentially affect the conformational orientation or access to the CES1 active site pocket (Imai et al. 2006 ).
Dabigatran etexilate is a unique prodrug requiring hydrolysis at two sites to form the active direct thrombin inhibitor. A recent analysis demonstrating that both stroke and bleeding risk in patients with atrial fibrillation are directly linked to DAB plasma concentrations suggests that understanding DABE's metabolic pathway and factors affecting it are crucial for assessing benefits and risks of therapy .
We attempt to address this issue in this report with our results showing that both CES1
and CES2 are essential for DAB active metabolite formation. Characterizing this drug's metabolic pathway is a crucial first step in identifying how factors affecting the activity of CES1 and CES2 may have important effects on this drug's disposition, and in turn, efficacy and safety. The common assumption applied to DABE and other carboxylesterase substrate drugs is that these agents are not subject to significant 
